Reuters: Regulatory News: EU agency backs new cancer drugs from Roche and Algeta/Bayer

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Free Bestselling eBooks Free national bestsellers for your eReader - Fiction, Nonfiction & more! Join 1.5 million book lovers now. Sign-up in under 10 seconds to get the free daily email. From our sponsors

EU agency backs new cancer drugs from Roche and Algeta/Bayer Sep 20th 2013, 11:31 LONDON, Sept 20 | Fri Sep 20, 2013 7:31am EDT LONDON, Sept 20 (Reuters) - European regulators have recommended approval of Roche's new breast cancer drug Kadcyla and a prostate cancer medicine, Xofigo, from Algeta and Bayer. The European Medicines Agency (EMA) said on Friday its experts had also backed Johnson & Johnson's diabetes drug Invokana and Gilead's HIV treatment Viteka. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions